Kindeva Acquires Intranasal Drug Delivery CDMO Summit Biosciences

Kindeva Drug Delivery has acquired Summit Biosciences, an intranasal drug-delivery contract development and manufacturing organization (CDMO) from its founding family shareholders.
 
Kindeva said acquiring Summit boosts its existing drug delivery capabilities with a new drug delivery platform, expanding its ability to serve biopharma customers across pulmonary, injectable, transdermal, and nasal drug-device combo products.
 
Summit adds a 55,000-square-foot cGMP facility located in Lexington, Ky. to Kindeva’s nine development and manufacturing facilities in the U.S. and UK. The facility is approved by both the FDA and European Medicines Agency, and has specialized labs and integrated manufacturing operations.
 
“Nasal drug delivery is becoming a preferred dosage format for a growing number of indications, as it allows users to non-invasively administer medications in an acute or emergency setting,” said Kindeva CEO Milton Boyer. “Summit brings a differentiated understanding of how to effectively formulate drugs for nasal delivery and the capability to manufacture them at commercial scale. This addition not only fits Kindeva’s ambition to be a global leader in the drug-device combination products CDMO market, but also expands the toolbox we can offer our customers to help improve patient outcomes and experience of care globally.”
 
Departing Summit chairman and CEO Richard D. Cohen added, “Joining Kindeva strengthens our ability to deliver best-in-class nasal product development and manufacturing. Under Kindeva’s leadership, our dedicated and talented workforce will further drive our founder’s vision of increasing the availability of nasal drug-delivery options.”